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Valve prosthesis–patient mismatch (VP–PM) was first de-
scribed in 1978 (1) by Dr. Rahimtoola, who had the
foresight of elaborating from case observations a very
important concept that has indeed become an accepted part
of the clinical aspect of prosthetic heart valve implantation
and has undoubtedly contributed to improving the outcome
of patients undergoing heart valve surgery. Nonetheless and
See page 1123
for reasons more or less evident, the clinical relevance of this
basic and logical concept still remains controversial after 30
years of research. It is thus most appropriate in this context
that Drs. Daneshvar and Rahimtoola were commissioned by
the Journal to write a viewpoint article (2) summarizing
heir actual perspective with regard to VP–PM. We feel
rivileged to also having been invited by the Journal to write
commentary on this topic.
How Should VP–PM Be Measured?
Inherently consistent with the concept of VP–PM is that it
should be identified by a parameter taking into account both
the expected hemodynamic performance of the prosthesis
and the cardiac output requirements of the patient, which at
rest are largely related to body size (1). Indeed, it is the
extent of the mismatch between these 2 variables that
determines the eventual consequences that may be associ-
ated with high post-operative gradients. Hence, a prosthesis
that might be adequate for a small patient (e.g., a child)
might become obstructive for a large patient (e.g., a tall
patient with a body surface area 2.0 m2), and, therefore,
the only parameter that has proven to be consistently and
realistically useful for this purpose is the indexed effective
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paper to disclose.orifice area (EOAi). As pointed out by Daneshvar and
Rahimtoola (2), there are nonetheless many caveats to be
emphasized with regard to this measurement. First, the
hemodynamic performance of the prosthesis is determined
by the effective orifice area (EOA), which is the area
occupied by flow, whereas its relation to the geometric
orifice area of the prosthesis or the diameter of its sewing
ring may vary considerably depending on the design and
materials used; hence, as evidenced in the online supple-
mental tables of Daneshvar and Rahimtoola (2), the ob-
served EOAs for a given size of prosthesis may vary largely
from one type of prosthesis to the other (e.g., from 1.6 to
2.0 cm2 for bioprostheses with labeled size 23). Second, the
bserved EOAs for a given type and size of normally
unctioning prostheses may show a wide range of values that
ay be in relation to one or more of the following: 1) the
nherent variability and technical difficulties associated with
oppler echocardiographic measurements; 2) the “patho-
ogical healing” of the prosthesis, which may vary from one
rosthesis to the other; 3) central localized high-velocity jet
n bilealflet mechanical prostheses; 4) variations in the
elative opening of the leaflets in relation to the balance
etween their resistive properties and the impetus provided
y left ventricular (LV) outflow, which may lead to “pseudo-
everization” of the valve EOA in the case of low-flow
tates. Notwithstanding these considerations, the clinical
iagnosis of VP–PM would not be possible without the use
f reference values such as those presented in the aforemen-
ioned tables. Indeed, these values serve as a benchmark
epresenting the intrinsic valve hemodynamic performance
f a given type and size of prosthesis. Hence, a post-
perative EOAi of 0.75 cm2/m2 in an individual with a
body surface area of 2.0 m2 would be considered as
oderate VP–PM if he had been implanted with a size 23
orin Mitroflow (reference EOA: 1.54 cm2), whereas one
would have to question whether there was not an intrinsic
dysfunction of the prosthesis or an error in measurements if
he had been implanted with a size 23 Sorin Freedom Solo
prosthesis (reference value: 2.0 cm2) because the projected
OAi in this case would have been 1.0 cm2/m2. The clinical
implications would not necessarily be the same in the 2
patients and, in the absence of an error in measurement, the
second patient would require at least a closer longitudinal
follow-up to determine whether there was not an underlying
obstructive process. Despite its limitations, the confronta-
tion of the observed EOAi to the projected EOAi is thus
essential to distinguish VP–PM from intrinsic dysfunction
and would have become even more relevant if, for instance,
the same individual had received a size 23 St. Jude Medical
Regent with a reference value of 2.2 cm2, in which case the
projected EOAi would have been 1.1 cm2/m2 compared
ith the observed 0.75 cm2/m2. Hence, it is thus not a
question of which is the best parameter between the
post-operatively measured EOAi and the projected EOAi.
Rather, because the measured EOAi in a given patient may
http://dx.doi.org/10.1016/j.jacc.2012.07.005be influenced by multiple factors other than VP–PM, it is
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terizing the intrinsic hemodynamic performance of the
prosthesis.
As Daneshvar and Rahimtoola (1), we have always
insisted that normal reference values should be based on
reliable datasets from clinical trials having an adequate
number of subjects and that manufacturer-provided values
are often too optimistic (3–6). Notwithstanding these
limitations, the projected EOAi is at present the only
parameter that has been found to be valid for the purpose of
adequately diagnosing VP–PM in the individual patient as
well as to predict and prevent the occurrence of VP–PM.
Assessment of Severity of VP–PM
The vast majority of studies that examined the prevalence
and clinical impact of VP–PM used EOAi cutpoint values
of 0.85 cm2/m2 and 0.65 cm2/m2 for the definition of
oderate and severe VP–PM, respectively, and many of
hese studies (7–13) as well as 2 recent meta-analyses
14,15) demonstrated that VP–PM defined according to
hese criteria predicts outcomes. In the meta-analysis by
ead et al. (14), 27 of the 34 included studies (79%) used
he 0.85 cm2/m2 cutpoint value to identify VP–PM, and in
hose published in or after 2006, 85% (23 of 27) used this
alue. Furthermore, the 2009 American Society of Echo-
ardiography/European Association of Echocardiography
ecommendations for the Doppler echocardiographic eval-
ation of prosthetic valves have also endorsed these defini-
ions of VP–PM (16). Consequently, many have argued that
hese values should continue to be used to allow better
omparison between past and future studies. It should also
e of no surprise and somewhat reassuring that these values
re very close to those used in the case of native aortic
tenosis (AS). Nonetheless, there is no evidence in the
iterature that 0.90 cm2/m2 is better than 0.85 cm2/m2 to
define moderate VP–PM or that 0.6 cm2/m2 is better than
0.65 cm2/cm2 to define severe VP–PM (12,14,15). Further-
ore, given the small differences in these cutoff values, this
ebate is more one of semantics than a major issue that
ould really affect the interpretation of data. In this context,
t is also interesting to note that the authors of the 1988
arge series of patients (17) mentioned by Daneshvar and
ahimtoola (2) with regard to validation of the 50-mm Hg
nd 0.6-cm2/m2 threshold values for severe AS had the
foresight to emphasize their results as follows: “The corre-
lation between valve area and aortic gradients was poor. No
gradient was found that was both sensitive and specific for
aortic stenosis . . . Patients with severe aortic stenosis and
low gradients (peak or mean gradient of less than 30 mm Hg)
had small ventricles (on both angiographic and echocardio-
graphic data) with good ejection fractions and so were
unlikely to be detected subjectively . . . The aortic valve area
should be measured in all patients with the suspicion of
severe aortic stenosis with a mean gradient of 50 mm Hg
(50% of patients in this study) or a peak gradient of60 mm Hg(47% of patients in this study).” The threshold value for severe
AS in that study was aortic valve area 0.9 cm2, and there
were no outcome data. The value of 0.6 cm2/m2 appeared
later in a review article by Rahimtoola (18), and the 1973
natural history study of Frank et al. (19) included only 15
patients and actually used a threshold of 0.7 cm2/m2.
When Should Severity of VP–PM Be Determined?
There was a definite consensus among the echocardiogra-
phers who wrote the American Society of Echocardiogra-
phy/European Association of Echocardiography recom-
mendations for the evaluation of valve prosthesis (16) that
“ideally, a baseline post-operative transthoracic echocardio-
graphic study should be performed at the first visit, 2 to 4
weeks after hospital discharge, when the chest wound has
healed, ventricular function has improved, and anemia with
its attendant hyperdynamic state has abated.” Reassessment
for VP–PM at 6 to 12 months might also be useful, but the
results should then also be compared with the baseline
values and the reference values for the given type and size of
prosthesis to appreciate the effects of the pathological
healing process as well as to eliminate the possibility of an
intrinsic obstructive process. These considerations further
underline that reference values should be derived from large
and reliable datasets because there will always be outliers
due to technical or pathological issues.
Impact of VP–PM on Outcomes
The projected EOAi was identified by Bleiziffer et al. (20)
as being the best parameter to predict the occurrence
VP–PM after operation. The study of Florath et al. (21)
used by some investigators to downplay the projected EOAi
included only patients with stentless bioprostheses whose
intrinsic hemodynamic performance after implantation de-
pends much more on the anatomy of the patient’s aortic
annulus/root and the type and quality of the surgical
technique than stented prostheses. Hence, most studies of
outcomes used the projected EOAi because it provides a
standardized analysis of the intrinsic performance of a given
prosthesis and also allows an analysis of the VP–PM on
operative mortality (14). In addition to the pros and cons of
each parameter (measured vs. projected EOAi) discussed
previously, the utilization of the measured EOAi to define
VP–PM also introduces an important survival bias that may
lead to an underestimation of the impact of VP–PM on
survival. Indeed, the patients who died during the periop-
erative period generally did not have a measurement of
EOAi after operation and were therefore excluded from
analysis. Hence, it is not surprising that the studies that used
the measured EOAi generally did not find any significant
impact on 30-day mortality, whereas several other studies
reported that severe VP–PM defined with the projected
EOAi is a powerful independent predictor of 30-day mor-
tality after aortic valve replacement (AVR) (8,9,12). More-
over, 2 recent meta-analyses (14,15) unequivocally showed
1138 Pibarot and Dumesnil JACC Vol. 60, No. 13, 2012
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all-cause and cardiac long-term mortality after AVR, with
the larger meta-analysis (14) also showing that moderate
VP–PM also has a significant but weaker impact on the
same outcomes. As emphasized by Daneshvar and Rahim-
toola (2), the effect of moderate VP–PM on survival may be
mediated through the coexistence of acquired prosthetic
valve stenosis because the addition of a moderately stenotic
process to a valve that is already moderately stenotic due to
VP–PM might indeed result in a severely increased hemo-
dynamic burden having detrimental effects on LV function
and survival. In this context, Flameng et al. (22) also
demonstrated that VP–PM may accelerate the development
of valve stenosis in bioprostheses, thereby suggesting the
presence of a synergistic interaction between VP–PM and
valve stenosis. Moreover, as emphasized by many studies
(7,8,11,12,23,24), there is also a strong interaction between
VP–PM and depressed LV function with regard to early
and late mortality as well as to the occurrence of heart failure
to the extent that the impact of moderate and severe
VP–PM is much worse in patients with depressed LV
function. This observation is consistent with the concept
that moderate VP–PM (or moderate AS) is generally well
tolerated by patients with normal LV function but not
necessarily by patients with depressed LV function, severe LV
concentric hypertrophy, and/or concomitant mitral regurgita-
tion (7,8,12,24–26).
We strongly agree with Daneshvar and Rahimtoola that
patients with VP–PM often have important comorbidities
and that meticulous multivariable analyses should always be
performed when examining the relationship between
VP–PM and outcomes. In this regard, most of the studies
that performed such analyses or used more advanced statis-
tical methods such as bootstrap resampling and propensity
score adjustment concluded that VP–PM is independently
and significantly associated with outcomes (8,10–15,23).
These considerations thus underline that, when proper
analyses are performed using the right methodology, the
evidence that VP–PM has an important impact on out-
comes is indeed overwhelming (14,15).
Prevention of VP–PM
One of the major objectives arising from the elaboration of
the concept of VP–PM was the eventual ability to predict
and prevent its occurrence and thus improve patient out-
comes (1). This is now possible by calculating, at the time of
the operation, the projected EOAi with the proviso that
reliable sources of normal reference values of EOA are used
for this calculation (4,5). As recently outlined (5) and in
light of the comprehensive analysis of the data published
in the literature, severe VP–PM should ideally be avoided in
every patient undergoing AVR and moderate VP–PM in
the subsets of patients who are highly vulnerable to the
effect of VP–PM (i.e., patients with poor LV ejection
fraction, severe concentric hypertrophy, mitral regurgita-tion, and/or very severe AS at baseline) (7,8,12,24–26). In
1978, when the VP–PM was first described (1), the arma-
mentarium available to the surgeon for the prevention of
VP–PM was very limited, and aortic root enlargement was
essentially the sole option to avoid VP–PM or reduce its
severity. In 2012, given the significant improvements in
prostheses design, contemporary prevention of VP–PM can
largely be accomplished by the implantation of prosthetic
models providing a better hemodynamic performance. The
study by Bleiziffer et al. (20) is particularly illustrative in this
regard whereby these investigators were able to reduce the
incidence of moderate VP–PM from 44% to 30% and that
of severe VP–PM from 9% to 1% by applying this strategy.
Nonetheless, the use of an alternative procedure to avoid
VP–PM should always be considered in light of the risk-
benefit ratio and should not be done at expense of increased
operative risk or reduced prosthetic valve durability. On the
other hand, the calculation of the projected EOAi at the
time of the operation may also help to validate the use of a
small prosthesis in patients with small body size and hence
avoid more invasive procedures, such as aortic root enlarge-
ment (27,28).
Conclusions
VP–PM can be accurately identified and predicted with
appropriate uses of both the measured EOAi and the
projected EOAi. It is essential that the latter be derived
from reliable sources of normal reference EOAs. Severe
VP–PM has a significant impact on early and late mortality,
whereas moderate VP–PM may have a significant effect on
mortality in vulnerable subsets of patients, and particularly
in those with depressed LV systolic function. The preven-
tive strategy to avoid VP–PM can be implemented success-
fully and should be individualized according to the antici-
pated severity of VP–PM and of the patient’s baseline risk
profile.
We are grateful to Dr. Rahimtoola for having introduced
this concept 30 years ago. Indeed, the increasing aware-
ness of VP–PM has likely contributed to the improvement
of the hemodynamic performance of prosthetic valves and of
the outcomes of patients undergoing AVR. Beyond 2012,
we hope that progress in the design of prosthetic valves and
in the effectiveness of the surgical/transcatheter valve pro-
cedures will render the problem of VP–PM obsolete.
Reprint requests and correspondence: Dr. Philippe Pibarot and
Dr. Jean G. Dumesnil, Québec Heart and Lung Institute, 2725
Chemin Sainte-Foy, Québec G1V-4G5, Canada. E-mail:
philippe.pibarot@med.ulaval.ca or jean.dumesnil@med.ulaval.ca.
REFERENCES
1. Rahimtoola SH. The problem of valve prosthesis-patient mismatch.
Circulation 1978;58:20–4.
2. Daneshvar SA, Rahimtoola SH. Valve prosthesis–patient mismatch (VP–
PM): a long-term perspective. J Am Coll Cardiol 2012;60:1123–35.
1139JACC Vol. 60, No. 13, 2012 Pibarot and Dumesnil
September 25, 2012:1136–9 Valve Prosthesis–Patient Mismatch, 1978 to 20113. Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of
prosthesis-patient mismatch in the aortic valve position and its
prevention. J Am Coll Cardiol 2000;36:1131–41.
4. Pibarot P, Dumesnil JG. Prevention of valve prosthesis–patient mis-
match before aortic valve replacement: does it matter and is it feasible?
Heart 2007;93:549–51.
5. Dumesnil JG, Pibarot P. Prosthesis-patient mismatch: an update.
Curr Cardiol Rep 2011;13:250–7.
6. House CM, Nelson WB, Kroshus TJ, Dahiya R, Pibarot P.
Manufacturer-provided effective orifice area index charts and the
prevention of prosthesis-patient mismatch. J Heart Valve Dis 2012;
21:107–11.
7. Ruel M, Al-Faleh H, Kulik A, Chan K, Mesana TG, Burwash IG.
Prosthesis-patient mismatch after aortic valve replacement predomi-
nantly affects patients with pre-existing left ventricular dysfunction:
effect on survival, freedom from heart failure, and left ventricular mass
regression. J Thorac Cardiovasc Surg 2006;131:1036–44.
8. Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P.
Impact of valve prosthesis-patient mismatch on short-term mortality
after aortic valve replacement. Circulation 2003;108:983–8.
9. Walther T, Rastan A, Falk V, et al. Patient prosthesis mismatch affects
short- and long-term outcomes after aortic valve replacement. Eur
J Cardiothorac Surg 2006;30:15–9.
10. Kohsaka S, Mohan S, Virani S, et al. Prosthesis-patient mismatch
affects long-term survival after mechanical valve replacement. J Thorac
Cardiovasc Surg 2008;135:1076–80.
11. Mohty D, Dumesnil JG, Echahidi N, et al. Impact of prosthesis-
patient mismatch on long-term survival after aortic valve replacement:
influence of age, obesity, and left ventricular dysfunction. J Am Coll
Cardiol 2009;53:39–47.
12. Urso S, Sadaba R, Aldamiz-Echevarria G. Is patient-prosthesis
mismatch an independent risk factor for early and mid-term overall
mortality in adult patients undergoing aortic valve replacement?
Interact Cardiovasc Thorac Surg 2009;9:510–8.
13. Tasca G, Mhagna Z, Perotti S, et al. Impact of prosthesis-patient
mismatch on cardiac events and midterm mortality after aortic valve
replacement in patients with pure aortic stenosis. Circulation 2006;
113:570–6.
14. Head S, Mokhles M, Osnabrugge R, et al. The impact of prosthesis-
patient mismatch on long-term survival after aortic valve replacement:
a systematic review and meta-analysis of 34 observational studies
comprising 27 186 patients with 133 141 patient-years. Eur Heart J
2012;33:1518–29.
15. Takagi H, Yamamoto H, Iwata K, Goto SN, Umemoto T. A
meta-analysis of effects of prosthesis-patient mismatch after aortic
valve replacement on late mortality. Int J Cardiol 2012;159:150–4. h16. Zoghbi WA, Chambers JB, Dumesnil JG, et al. Recommendations for
evaluation of prosthetic valves with echocardiography and doppler
ultrasound: a report From the American Society of Echocardiography’s
Guidelines and Standards Committee and the Task Force on Pros-
thetic Valves. J Am Soc Echocardiogr 2009;22:975–1014.
17. Griffith MJ, Carey C, Coltart DJ, Jenkins BS, Webb-Peploe MM.
Inaccuracies in using aortic valve gradients alone to grade severity of
aortic stenosis. Br Heart J 1989;62:372–8.
18. Rahimtoola SH. Perspective on valvular heart disease: an update. J Am
Coll Cardiol 1989;14:1–23.
19. Frank S, Johnson A, Ross JJJ. Natural history of valvular aortic
stenosis. Br Heart J 1973;35:41–6.
20. Bleiziffer S, Eichinger WB, Hettich I, et al. Prediction of valve
prosthesis-patient mismatch prior to aortic valve replacement: which is
the best method? Heart 2007;93:615–20.
21. Florath I, Albert A, Rosendahl U, Ennker IC, Ennker J. Impact of
valve prosthesis-patient mismatch estimated by echocardiographic-
determined effective orifice area on long-term outcome after aortic
valve replacement. Am Heart J 2008;155:1135–42.
22. Flameng W, Herregods MC, Vercalsteren M, Herijgers P, Bogaerts
K, Meuris B. Prosthesis-patient mismatch predicts structural valve
degeneration in bioprosthetic heart valves. Circulation 2010;121:
2123–9.
23. Bleiziffer S, Ali A, Hettich IM, et al. Impact of the indexed effective
orifice area on mid-term cardiac-related mortality after aortic valve
replacement. Heart 2010;96:865–71.
24. Girerd N, Mathieu P, Dumesnil JG, et al. Impact of aortic stenosis
severity and its interaction with prosthesis-patient mismatch on
operative mortality following aortic valve replacement. J Heart Valve
Dis 2012;21:158–67.
25. Unger P, Magne J, Vanden Eynden F, et al. Impact of prosthesis-
patient mismatch on mitral regurgitation after aortic valve replace-
ment. Heart 2010;96:1627–32.
26. Angeloni E, Melina G, Pibarot P, et al. Impact of prosthesis-patient
mismatch on the regression of secondary mitral regurgitation after
isolated aortic valve replacement with a bioprosthetic valve in patients
with severe aortic stenosis. Circ Cardiovasc Imaging 2012;5:36–42.
27. Yoshikawa K, Fukunaga S, Arinaga K, et al. Long-term results of
aortic valve replacement with a small St. Jude Medical valve in
Japanese patients. Ann Thorac Surg 2008;85:1303–8.
28. Dumesnil JG, Pibarot P. Invited commentary. Ann Thorac Surg
2008;85:1308–9.Key Words: aortic stenosis y Doppler echocardiography y prosthetic
eart valve y surgery.
